FDA’s Accelerated Approval Program creates an opportunity to bring promising treatments for serious conditions to patients sooner. Yet the pathway introduces a consequential planning challenge: the evidence that supports initial approval and the evidence required to verify clinical benefit must...
Tag: FDA 2 results
The U.S. Food and Drug Administration’s (FDA) renewed focus on drug repurposing is bringing fresh attention to a regulatory pathway that has quietly shaped drug development for decades: 505(b)(2). Starting out as a critical mechanism bridging the gap between traditional 505(b)(1) new drug applications and abbreviated...